F8 and hemophilia A: EPCs are an attractive resource for enhancing neovascularization in ischemic tissue and producing FVIII in cases of hemophilia A. However, the low number of cells obtained after purification from peripheral or cord blood is a common barrier to the clinical use of EPCs.